Clinical trials: Axillary Hidradenitis Suppurativa
Hidradenitis Suppurativa
Pathophysiological Basis of Hidradenitis Suppurativa
HS is a chronic inflammatory disease manifested by recurrent inflammatory nodules, abscesses and tunnels under the skin. This disease is characterized by an inflammatory process that takes place in hair follicles, sebaceous…
- Trial name
- NCT06370052
- Testing
- excision
- Volunteers
- 50 people
- Sponsor
- Clinical Hospital Center Rijeka
Crohn Disease, Ulcerative Colitis
The Evaluation of Injection Site Pain and Adherence in Patients Switching From a Low To High Concentration Adalimumab (AVT-02) Across Multiple Indications.
The purpose of the Phase IV study is to investigate the effects of both Volume and Citrate on Injection Site Pain (ISP), adherence, patient satisfaction, Quality of Life, and Disease Assessment in the Canadian Adalimumab Market.
- Conditions
- Crohn Disease, Ulcerative Colitis, Rheumatoid Arthritis, Ankylosing Spondylitis
- Trial name
- EASE PAIN (NCT05913817)
- Testing
- AVT02 (Alvotech Biosimilar to Adalimumab)
- Where
- Canada
- Volunteers
- 324 people
- Sponsor
- Jamp Pharma Corporation
Axillary Hidradenitis Suppurativa
Perforator Flaps for Axillary Hidradenitis Suppurativa
Hidradenitis Suppurativa (HS) is a recurrent inflammatory disease (< 2 episode /6 months) with 1%-4% prevalence in Europe. Suppurating lesions are painful and involve one or more regions (axilla, genitofemoral, perineum, gluteal…
- Trial name
- HS-PAX (NCT03784313)
- Testing
- skin repair by axillary perforator flaps, skin repair by secondary wound healing
- Where
- France
- Volunteers
- 88 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Hidradenitis Suppurativa (HS)
Participants with Mild to Moderate Hidradenitis Suppurativa Will Receive EVO101 a Topical Cream 0.1%
The goal of this clinical trial is to learn if drug EVO101 works to treat mild to moderate hidradenitis suppurativa in adults. The main questions it aims to answer are: Does drug EVO101 lower the total number of lesion a…
- Trial name
- NCT06645821
- Testing
- EVO101
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Virginia Clinical Research, Inc.
Hidradenitis Suppurativa
A Study of the Safety of INCB054707 in Participants With Hidradenitis Suppurativa
The purpose of this study is to assess the safety of INCB054707 in men and women with moderate to severe hidradenitis suppurativa (HS).
- Trial name
- NCT03569371
- Testing
- INCB054707
- Where
- 4 sites in United States
- Volunteers
- 10 people
- Sponsor
- Incyte Corporation
Hidradenitis Suppurativa
Battlefield Acupuncture for Pain in Hidradenitis Suppurativa
The investigators will investigate battlefield acupuncture as a treatment for the pain of hidradenitis suppurativa.
- Trial name
- NCT04218422
- Testing
- Battlefield Acupuncture
- Where
- United States
- Volunteers
- 32 people
- Sponsor
- Wayne State University
Hidradenitis, Healthy Volunteers
SAR447971 First-in-human Study
SAD20411 is a single-center, first-in-human, double-blind, randomized, placebo-controlled, sequential single ascending dose study in healthy male and/or female participants with a pilot food effect investigation.
- Trial name
- NCT07629336
- Testing
- SAR447971
- Where
- Netherlands
- Volunteers
- 114 people, healthy volunteers welcome
- Sponsor
- Sanofi
Atopic Dermatitis, Hidradenitis Suppurativa (HS)
A Phase I Study of QLS12010 Capsules: Safety, Tolerability, PK, PD, and Food Effects in Healthy Adults and Moderate to Severe Atopic Dermatitis Patients
The goal of this clinical trial is to evaluate the safety, tolerability, PK, and PD of single and multiple ascending doses of QLS12010 Capsules and the effect of food on their PK profiles in healthy adult participants and…
- Conditions
- Atopic Dermatitis, Hidradenitis Suppurativa (HS), Rheumatoid Arthritis (RA)
- Trial name
- NCT06946641
- Testing
- QLS12010
- Where
- China
- Volunteers
- 102 people, healthy volunteers welcome
- Sponsor
- Shanghai Qilu Pharmaceutical Research and Development Center LTD
Hidradenitis Suppurativa
Treatment of Moderate Hidradenitis Suppurativa
The study will be conducted over 24 weeks on active therapy followed by a four-week observational visit. The total length of the study will be 28 weeks.
- Trial name
- NCT03910803
- Testing
- Brodalumab
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Florida Academic Dermatology Centers
Age-Related Macular Degeneration, Allergies
Tissue Repository Providing Annotated Biospecimens for Approved Investigator-directed Biomedical Research Initiatives
To collect, preserve, and/or distribute annotated biospecimens and associated medical data to institutionally approved, investigator-directed biomedical research to discover and develop new treatments, diagnostics, and…
- Conditions
- Age-Related Macular Degeneration, Allergies, Alpha-Gal Syndrome, Alzheimer Disease
- Trial name
- NCT05635266
- Testing
- Specimen sample
- Where
- United States
- Volunteers
- 20,000 people, healthy volunteers welcome
- Sponsor
- Sanguine Biosciences
Psoriasis, Atopic Dermatitis
LANDSCAPE: Demographics and Treatment Patterns of Patients With Immune-Mediated Inflammatory Skin Diseases in Italian Clinical Practice
This multicenter retrospective observational registry study will collect existing clinical data from Italian centers to describe epidemiology, treatment patterns, clinical evolution, safety, and comorbidities in patients aged 12…
- Conditions
- Psoriasis, Atopic Dermatitis, Vitiligo, Alopecia Areata
- Trial name
- LANDSCAPE (NCT07336641)
- Testing
- Conventional Systemic Therapies, Biologic Therapies
- Where
- Italy
- Volunteers
- 20,000 people
- Sponsor
- Fondazione ISIDE
Hidradenitis Suppurativa
Single Center Study of Apremilast for the Treatment of Hidradenitis Suppurativa
The primary objective of this study is to evaluate the safety and efficacy of Apremilast in subjects with moderate Hidradenitis Suppurativa (HS).
- Trial name
- HS (NCT02695212)
- Testing
- Apremilast
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Florida Academic Dermatology Centers
Hidradenitis Suppurativa
Assessing Short-term Treatment Satisfaction and Quality of Life in Patients With Hidradenitis Suppurativa Initiated on Secukinumab.
This study will be conducted to address the lack of concrete data on the impact of pharmaceutical intervention on short-term patient satisfaction and quality of life (QoL) in patients with Hidradenitis Suppurativa (HS) in…
- Trial name
- NCT06785675
- Testing
- Secukinumab
- Where
- 4 sites in United Arab Emirates
- Volunteers
- 53 people
- Sponsor
- Novartis Pharmaceuticals
Hidradenitis Suppurativa
A Randomized Controlled Trial Evaluating the Efficacy of Intralesional Triamcinolone in Hidradenitis Suppurativa.
Purpose: To evaluate the effectiveness of intralesional triamcinolone for the treatment of hidradenitis suppurativa (HS) Participants: Patients diagnosed with Hidradenitis Suppurativa that have active inflammatory HS lesions.
- Trial name
- NCT02781818
- Testing
- Triamcinolone Acetonide 10mg/mL, Triamcinolone Acetonide 40mg/mL, Normal Saline
- Where
- United States
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- University of North Carolina, Chapel Hill
Hidradenitis Suppurativa
Control of Hidradenitis Suppurativa of the Underarms After Combination Deroofing and Laser
The purpose of the study is to determine whether a series of laser hair removal treatments can improve participant outcomes after deroofing procedures.
- Trial name
- NCT05484674
- Testing
- Deroofing and laser
- Volunteers
- 6 people
- Sponsor
- University of Texas at Austin
Hidradenitis Suppurativa
Studying Complement Inhibition in Patients With Moderate to Severe Hidradenitis Suppurativa
The trial enrolls patients with moderate to severe Hidradenitis Suppurativa (HS). The primary goal of the trial is to evaluate the safety and tolerability of IFX-1 administered over 8 weeks in these patients.
- Trial name
- NCT03001622
- Testing
- IFX-1
- Where
- Greece
- Volunteers
- 12 people
- Sponsor
- InflaRx GmbH
Hidradenitis Suppurativa
A Study of the Efficacy and Safety of Brensocatib in Adults With Moderate to Severe Hidradenitis Suppurativa (HS)
The primary purpose of the study is to evaluate the effect of brensocatib compared with placebo.
- Trial name
- CEDAR (NCT06685835)
- Testing
- Brensocatib
- Where
- 72 sites in United States, Australia and 8 more
- Volunteers
- 214 people
- Sponsor
- Insmed Incorporated
Hidradenitis Suppurativa
Assessment of the Safety, Tolerability and Efficacy of MEDI8968 in Subjects With Moderate to Severe Hidradenitis Suppurativa
The purpose of this study is to gain initial evidence for the safety, tolerability and efficacy of MEDI8968 for the treatment of subjects with moderate to severe hidradenitis suppurativa
- Trial name
- NCT01838499
- Testing
- MEDI8968, Saline
- Where
- 27 sites in United States
- Volunteers
- 224 people
- Sponsor
- AstraZeneca
Vitiligo, Atopic Dermatitis
An Observational Study of Patients With Dermatologic Disease
TARGET-DERM+ is an observational research study to conduct a comprehensive review of outcomes for patients with dermatologic disease (DD) and providers who treat these patients.
- Conditions
- Vitiligo, Atopic Dermatitis, Alopecia Areata, Hidradenitis Suppurativa (HS)
- Trial name
- TARGET-DERM+ (NCT07748169)
- Where
- United States
- Volunteers
- 2,000,000 people
- Sponsor
- Target PharmaSolutions, Inc.
Hidradenitis
Group Psychotherapy for Patients With Hidradenitis Suppurativa: Effects in Quality of Life
The aim of this study is to determine the benefits of group psychotherapy on quality of life for people with hidradenitis suppurativa receiving medical and surgical treatment versus a control group (awaiting group) treated with…
- Trial name
- NCT02904408
- Testing
- psychotherapy
- Where
- Spain
- Volunteers
- 120 people
- Sponsor
- Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau